insulin glargine vs SHR-3167
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin glargine · Lantus
Marketed by Sanofi
NCT00069784 · Phase 3 · completed
The trial randomized 12,537 participants and used adjudicated clinical cardiovascular events, but treatment assignment was open-label rather than double-blinded. Neither primary cardiovascular endpoint was statistically significant in favor of insulin glargine, so the evidence supports a well-powered but inconclusive or negative finding rather than strong evidence of benefit.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
No aligned efficacy figure on record for this race.
SHR-3167
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06688123 · Phase 2 · completed
The study randomized 275 adults with type 2 diabetes to once-weekly SHR-3167 (two titration schemes) or daily insulin glargine in an open-label, treat-to-target design. Its primary endpoint was change in HbA1c at week 20, a regulator-accepted measure in type 2 diabetes. Hengrui reports HbA1c reductions similar to glargine (differences -0.02% and -0.14%, with both confidence intervals crossing zero), but neither the registry nor the company states a non-inferiority margin, so whether the primary comparison was met cannot be called. The figures are company-reported and not peer reviewed.
Company release of an EASD 2026 late-breaking abstract; not peer reviewed and not posted on the registry.
Next expected readout: December 2026 · NCT07472725 (registry estimate)
Reported efficacy
Change from baseline to week 20 in HbA1c (HemoglobinA1c) (Week 0 to week 20.): Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated.
Result source: NCT06688123
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin glargine | SHR-3167 |
|---|---|---|
| HbA1c, change | -0.6% vs -0.8%vs Insulin IcodecNCT0634085418 other results
| —Trial running · NCT07913061 |
| Body weight, change (kg) | 0.6 vs 2.0vs Insulin IcodecNCT063408547 other results
| —Trial running · NCT07913061 |
| HbA1c below 7% | 48.4% vs 45.9%vs LiraglutideNCT011173504 other results
| —Trial running · NCT07913061 |
| Fasting plasma glucose, change | -3.6 vs -2.1vs LiraglutideNCT011173504 other results
| —Trial running · NCT07913061 |
| 3-point MACE (% with event) | —Not posted · NCT00044447 | —Trial running · NCT07913061 |
HbA1c, change
- insulin glargine
- -0.6% vs -0.8%vs Insulin IcodecNCT06340854
18 other results
- -1.0% vs -1% NCT05462756
- -1.0% vs -1% NCT05462756
- -1.7% vs -1.4% NCT00391027
- -2.0% vs -1.8% NCT00418522
- -1.7% vs -1.1% NCT00751114
- -1.3% vs -1.4% NCT00686712
- -1.9% vs -1.4% NCT00686712
- -1.3% vs -1.4% NCT02455076
- -1.1% vs -1.4% NCT02455076
- -1.9% vs -1.7% NCT00418522
- -1.9% vs -1.8% NCT01117350
- -2.5% vs -2.1% NCT00384085
- -0.4% vs -0.1% NCT00360698
- -1.7% vs -1.5% NCT00391027
- -1.6% vs -1.3% NCT00391027
- -1.3% vs -1.1% NCT00391027
- -0.8% vs -0.6% NCT00391027
- -0.4% vs -0.3% NCT00391027
- SHR-3167
- —Trial running · NCT07913061
Body weight, change (kg)
- insulin glargine
- 0.6 vs 2.0vs Insulin IcodecNCT06340854
7 other results
- 2.7 vs 2.5 NCT05462756
- 2.0 vs -3.0 NCT01117350
- 2.2 vs 1.1 NCT00391027
- 3.5 vs 2.3 NCT00418522
- 0.4 vs -1.1 NCT00751114
- 0.5 vs 0.2 NCT00360698
- -1 vs -0.5 NCT02455076
- SHR-3167
- —Trial running · NCT07913061
HbA1c below 7%
- insulin glargine
- 48.4% vs 45.9%vs LiraglutideNCT01117350
4 other results
- 22.4% vs 8.8% NCT00360698
- 51.1% vs 39.5% NCT00384085
- 62.6% vs 47.6% NCT00418522
- 67.9% vs 41.9% NCT00751114
- SHR-3167
- —Trial running · NCT07913061
Fasting plasma glucose, change
- insulin glargine
- -3.6 vs -2.1vs LiraglutideNCT01117350
4 other results
- -1.7 vs -3.3 NCT00391027
- -2.9 vs -3.0 NCT00418522
- -3.4 vs -1.1 NCT00751114
- -0.8 vs -0.8 NCT01226043
- SHR-3167
- —Trial running · NCT07913061
3-point MACE (% with event)
- insulin glargine
- —Not posted · NCT00044447
- SHR-3167
- —Trial running · NCT07913061
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. insulin glargine: 4 of 4 rows · SHR-3167: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin glargine |
|---|---|
| Dropout rate | 19.3%a NCT00069784 · Phase 3 show 29 more results11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence 1.3% NCT02561130 · Phase 4 · registry result, not featured evidence 8.5%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence —Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 2%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 8.6%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 15.2% NCT00751114 · Phase 4 · registry result, not featured evidence 12.3%0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 0%0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 23.5%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 33.3%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 44%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence — NCT00360698 · Phase 4 · registry result, not featured evidence · combination 18.5% NCT00391027 · Phase 4 · registry result, not featured evidence 37.9% NCT00418522 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination 1.5% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 9.3%Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 4.7% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | 1.7%a NCT00069784 · Phase 3 show 29 more results0.8% NCT05114590 · Phase 4 · registry result, not featured evidence — NCT04153981 · Phase 4 · registry result, not featured evidence — NCT02561130 · Phase 4 · registry result, not featured evidence 6.4%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence —Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 0%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1.2%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 0.8% NCT00751114 · Phase 4 · registry result, not featured evidence —0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence —0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 2.6%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 3.3%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 4%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence — NCT00360698 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT00391027 · Phase 4 · registry result, not featured evidence 3.2% NCT00418522 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination — NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 0.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Serious AEs | 4.9%a NCT00069784 · Phase 3 show 29 more results0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence 14.9%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence 22.9%Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 23.5%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination 2.3%Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence 3.1%Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1%Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 10.1%Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 0.6%Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 6.3% NCT00751114 · Phase 4 · registry result, not featured evidence 0%0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 0%0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 11.9%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 0%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 4%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT00391027 · Phase 4 · registry result, not featured evidence — NCT00418522 · Phase 4 · registry result, not featured evidence 0% NCT00467649 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 6.5%Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 5.3%Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 6.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | a hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence show 22 more resultsanaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence genitourinary infection 5.2% abdominal pain 3.9% injury 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence nausea 9.8% vomiting 5.9% NCT02455076 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.9% headache 5% diarrhoea 3.7% NCT01117350 · Phase 4 · registry result, not featured evidence nasopharyngitis 7.5% diarrhoea 3.1% headache 1.3% NCT01117350 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 1.8% nasopharyngitis 1.3% sinusitis 1% NCT01226043 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 8.8% sinusitis 7.5% oedema peripheral 5% NCT01226043 · Phase 4 · registry result, not featured evidence nasopharyngitis 3.6% upper respiratory tract infection 2.4% sinusitis 1.2% NCT01226043 · Phase 4 · registry result, not featured evidence headache 6.3% influenza 3.4% nasopharyngitis 3.4% NCT00751114 · Phase 4 · registry result, not featured evidence any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination any infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination symptomatic hypoglycemia 76.7% asymptomatic retinal hemorrhage 3.3% urinary tract infection 0% NCT00686712 · Phase 4 · registry result, not featured evidence symptomatic hypoglycemia 96% asymptomatic retinal hemorrhage 0% urinary tract infection 0% NCT00686712 · Phase 4 · registry result, not featured evidence hypoglycaemia 70.4% nasopharyngitis 13.3% cough 6.7% NCT00391027 · Phase 4 · registry result, not featured evidence hypoglycaemia 67.9% tremor 31.6% dizziness 18.9% NCT00418522 · Phase 4 · registry result, not featured evidence nausea 11.1% diarrhoea 5.6% hypertension 5.6% NCT00467649 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.8% diabetic retinopathy 7.3% diarrhoea 1.9% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 influenza 7.3% covid-19 5.3% hypertension 5.3% NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 drug titration error 9.8% urinary tract infection 6.3% influenza 5.8% NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nasopharyngitis 6.3% influenza 3.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin glargine
show 1 more result
+ 66 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glargine's landscape · SHR-3167's landscape